The US National Institute of Standards and Technology (NIST) has evaluated the use of Genomic Vision applications for genetic variant characterization
February 21 2023 - 7:00AM
GENOMICS | CELL & GENE THERAPIES |
BIOPRODUCTION
The US National Institute of Standards
and Technology (NIST) has evaluated the use of Genomic Vision
applications for genetic variant characterization
- Genomic Vision’s technology
demonstrated high accuracy for quantitative
analysis of genomic events
- This
paves the way to establish standardized
methods for cell characterization
Bagneux (France) –
Genomic Vision (FR0011799907 – GV, the “Company”), a
Euronext-listed biotechnology company that develops products and
services for the highly accurate characterization of DNA sequences,
is pleased to announce the successful evaluation of its DNA combing
technology by the US National Institute of Standards and Technology
(‘NIST’). The evaluation has confirmed the high accuracy of the
technology for quantitative analysis of genomic events at or
greater than 10 kilobases.
The NIST Genome Editing Consortium
(‘Consortium’) is a public-private partnership consortium hosted by
NIST to collaboratively address precompetitive genome editing
measurements and standards (reference standards, reference methods,
and reference data) needed to increase confidence in evaluating
genome editing and utilizing these technologies in research and
commercial products.
Within this Consortium, Genomic Vision’s Quality
Control Assay (‘QCA’) was employed to identify, characterize, and
quantify mid to large-size genomic variants occurring in a specific
human population. The results were compiled by NIST and compared to
other datasets obtained within the Consortium. NIST determined that
Genomic Vision’s technology produced high quality results. The
global results issued from the Consortium will be disclosed by NIST
in spring 2023.
Genomic Vision’s technology allows for highly
sensitive and digitally quantifiable analysis of structural and
functional genome modifications and provides a quality control tool
for the safety and optimization of engineered cells. The data
output enables an unbiased assessment of genetic events through
direct visualization of modifications on single DNA molecules.
Aaron Bensimon, Chief Executive Officer
of Genomic Vision, commented: “We are
pleased that our methodology for the characterization of naturally
occurring mutations has received further validation, going through
NIST’s rigorous interlaboratory study process blinded to the
details about the genomic variants to be detected and performing to
high standards. We believe our technology can become a gold
standard for structural and functional genome analysis, with
potential applications for quality control of cell and gene therapy
products and bioproduction.”
Samantha
Maragh, Ph.D., Project Leader of the
Genome Editing program at NIST, commented: “We are pleased
to be working with Genomic Vision, a member of the NIST Genome
Editing Consortium, and welcome their innovative QCA method of
genome characterization to help advance the genome editing field.
For this NIST Genome Editing Consortium Interlab Study,
organizations were given a set of blinded qualified samples
provided by NIST to assess their technologies. Genomic Vision’s
technology demonstrated high accuracy for quantitative analysis of
genomic events around 10 kilobases and greater.”
The Consortium numbers more than 40 academic and
industrial members and Genomic Vision has been part of the NIST
Consortium since 2019.
About Genomic Vision
GENOMIC VISION is a biotechnology company
developing products and services dedicated to the structural and
functional analysis of genome modifications as well as to the
quality and safety control of these modifications, in particular in
genome editing technologies and biomanufacturing processes. Genomic
Vision proprietary products and services, based on DNA combing
technology and artificial intelligence, provide robust quantitative
measurements needed for high confidence characterization of DNA
alteration in the genome. These products and services are also used
for monitoring DNA replication in cells to improve anti-cancerous
drugs development. Genomic Vision, based near Paris in Bagneux, is
a public company listed in compartment C of Euronext’s regulated
market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit
www.genomicvision.com
About the National Institute of Standards and Technology
(NIST)
The National Institute of Standards and
Technology (NIST) was founded in 1901 and is now part of the U.S.
Department of Commerce. NIST is one of the nation’s oldest physical
science laboratories, and addresses measurement research needs in
multiple fields including chemistry, IT, engineering and biology.
The NIST Genome Editing Consortium addresses the measurements and
standards needed to increase confidence of utilizing genome editing
technologies in research and commercial products
(www.nist.gov).
Genomic
VisionAaron BensimonCEOPhone: +33 1 49 08 07
51Email: investisseurs@genomicvision.com |
Consilium Strategic
CommunicationsInternational Investor Relations &
Strategic Communications Tel: +44 (0) 20 3709
5700GenomicVision@consilium-comms.com |
Ulysse CommunicationMedia RelationsBruno
ArabianTél. : +33 1 42 68 29
70barabian@ulysse-communication.com |
NewCapInvestor
relations Phone: +33 1 44 71 94
94Email: gv@newcap.eu |
|
|
Member of the CAC®
Mid & Small and CAC® All-Tradable indices
FORWARD LOOKING STATEMENT
This press release contains implicitly or
explicitly certain forward-looking statements concerning Genomic
Vision and its business. Such forward-looking statements are based
on assumptions that Genomic Vision considers to be reasonable.
However, there can be no assurance that such forward-looking
statements will be verified, which statements are subject to
numerous risks, including the risks set forth in the “Risk Factors”
section of the universal registration document filed with the AMF
on April 14, 2022 under reference number R.22-0293, as updated by
the amendment filed with the AMF on May 20, 2022, under number
D.22-0293-A01, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained
herein do not constitute and should not be construed as an offer or
an invitation to sell or subscribe, or the solicitation of any
order or invitation to purchase or subscribe for Genomic Vision
shares in any country. The distribution of this press release in
certain countries may be a breach of applicable laws. The persons
in possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Genomic Vision (EU:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genomic Vision (EU:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024